WALTHAM, Mass., March 17, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 2015 Canaccord Genuity Musculoskeletal Conference on March 24, 2015 at 3:30 pm Pacific time at the MGM Grand in Las Vegas.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics' website at www.histogenics.com. The webcast will be available on Histogenics' website for 90 days following the conference.
Histogenics will also be attending the 2015 Annual Meeting of the American Association of Orthopaedic Surgeons (AAOS) in Las Vegas, Nevada from March 24 through March 28. Throughout the conference, Histogenics plans to sponsor various meetings with investigators, surgeons and thought leaders to discuss its ongoing NeoCart® Phase 3 clinical trial, which is studying an investigational tissue implant in certain knee cartilage injuries.
About Histogenics Corporation
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics' regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics' first investigational product candidate, NeoCart, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.